SA Editor Douglas W. House
Contributor since: 2011
FDA Clinical Hold On Juno Therapeutics' JCAR015: Hiccup Or Fatal?
Organovo: Modest Expectations For The Liver Tox Assay
MusclePharm Fails To Pump Me Up
Twitter: A $74 Price Target?
Tengion: A Cautionary Tale For Regenerative Medicine Bulls
The Evolution Of Compugen: Is The Titan Arum Finally Ready To Bloom?
Harvard Bioscience Bulls Need A Lot Of HART
Can Trovagene Be The Belle Of The Ball?
Organovo: Get Rich Or Die Tryin'
Regenerative Medicine: Some Realism Please
3D Systems: Pardon Me, Sir - Could You Spare An Explanation?
3D Systems: Has The Printer Jammed?
Trovagene: For, Against Or Abstain?
Trovagene: More Smoke And Mirrors
Trovagene: Technology In A Cup?
SciClone Pharmaceuticals: Not Ready For Prime Time
MannKind: Will The Good News Ever Come?
Accretive Health: A Data Gaffe And (Maybe) Thinner Margins
Accretive Health: Rx For Hospitals' Bottom Line
MannKind Is a Buy, Despite Roller Coaster FDA News
Missed Signals: The Hard Lesson of China MediaExpress Holdings
Stratasys, 3D Systems and the Next Technological Revolution